Medicamen Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Medicamen Biotech has a total shareholder equity of ₹2.0B and total debt of ₹308.2M, which brings its debt-to-equity ratio to 15.4%. Its total assets and total liabilities are ₹2.9B and ₹940.4M respectively. Medicamen Biotech's EBIT is ₹151.5M making its interest coverage ratio 3.4. It has cash and short-term investments of ₹147.9M.
Key information
15.4%
Debt to equity ratio
₹308.17m
Debt
Interest coverage ratio | 3.4x |
Cash | ₹147.86m |
Equity | ₹2.00b |
Total liabilities | ₹940.37m |
Total assets | ₹2.95b |
Recent financial health updates
No updates
Recent updates
What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 28% Share Price Gain Is Not Telling You
May 21More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%
Mar 17Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 13Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 19There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price
Dec 03Financial Position Analysis
Short Term Liabilities: MEDICAMEQ's short term assets (₹1.6B) exceed its short term liabilities (₹910.3M).
Long Term Liabilities: MEDICAMEQ's short term assets (₹1.6B) exceed its long term liabilities (₹30.1M).
Debt to Equity History and Analysis
Debt Level: MEDICAMEQ's net debt to equity ratio (8%) is considered satisfactory.
Reducing Debt: MEDICAMEQ's debt to equity ratio has increased from 13.6% to 15.4% over the past 5 years.
Debt Coverage: MEDICAMEQ's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: MEDICAMEQ's interest payments on its debt are well covered by EBIT (3.4x coverage).